Curi RMB Capital LLC Has $330,000 Stock Holdings in STERIS plc $STE

Key Points

• Curi RMB Capital LLC sold 2,314 shares of STERIS plc, reducing its holdings by 61.4% to a total of 1,455 shares valued at $330,000.
• STERIS recently reported a quarterly earnings of $2.34 EPS, slightly exceeding the consensus estimate, alongside an 8.8% year-over-year revenue increase to $1.40 billion.
• The company announced a dividend increase to $0.63 per share, reflecting a 1.0% yield, with an upcoming payment date of September 26th.

Curi RMB Capital LLC decreased its stake in shares of STERIS plc (NYSE:STE - Free Report) by 61.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 1,455 shares of the medical equipment provider's stock after selling 2,314 shares during the quarter. Curi RMB Capital LLC's holdings in STERIS were worth $330,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of STE. Mercer Global Advisors Inc. ADV boosted its stake in STERIS by 4.4% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,756 shares of the medical equipment provider's stock worth $772,000 after buying an additional 157 shares in the last quarter. Cary Street Partners Financial LLC bought a new position in shares of STERIS during the 4th quarter worth about $80,000. Captrust Financial Advisors boosted its position in shares of STERIS by 65.7% during the 4th quarter. Captrust Financial Advisors now owns 16,743 shares of the medical equipment provider's stock valued at $3,442,000 after acquiring an additional 6,638 shares in the last quarter. Centiva Capital LP acquired a new stake in shares of STERIS during the 4th quarter valued at about $636,000. Finally, EP Wealth Advisors LLC increased its stake in STERIS by 20.1% in the fourth quarter. EP Wealth Advisors LLC now owns 1,011 shares of the medical equipment provider's stock valued at $208,000 after acquiring an additional 169 shares during the period. 94.69% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Stephens restated an "overweight" rating and set a $250.00 price target on shares of STERIS in a research note on Thursday, May 15th. Citigroup restated an "outperform" rating on shares of STERIS in a research report on Friday, May 16th. Morgan Stanley boosted their price target on STERIS from $276.00 to $295.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Jefferies Financial Group began coverage on STERIS in a research note on Thursday, May 29th. They set a "hold" rating and a $263.00 price objective for the company. Finally, KeyCorp lifted their price target on shares of STERIS from $277.00 to $288.00 and gave the company an "overweight" rating in a report on Tuesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $273.50.

STERIS Price Performance

NYSE:STE traded down $2.35 during mid-day trading on Friday, reaching $250.08. 774,374 shares of the company were exchanged, compared to its average volume of 461,316. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The stock has a market cap of $24.63 billion, a PE ratio of 38.30 and a beta of 0.95. STERIS plc has a 12 month low of $200.98 and a 12 month high of $253.00. The company has a fifty day moving average of $237.41 and a 200 day moving average of $233.09.

STERIS (NYSE:STE - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.36 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. STERIS's quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.03 earnings per share. On average, research analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 26th. Shareholders of record on Thursday, September 4th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Thursday, September 4th. This is a positive change from STERIS's previous quarterly dividend of $0.57. STERIS's dividend payout ratio is 38.59%.

Insider Transactions at STERIS

In related news, Director Cynthia L. Feldmann sold 3,495 shares of STERIS stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $241.56, for a total value of $844,252.20. Following the completion of the sale, the director directly owned 705 shares in the company, valued at $170,299.80. This trade represents a 83.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mohsen Sohi sold 4,110 shares of the business's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $241.96, for a total value of $994,455.60. Following the sale, the director directly owned 22,361 shares of the company's stock, valued at $5,410,467.56. This represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,709 shares of company stock valued at $4,546,940 over the last quarter. Corporate insiders own 1.07% of the company's stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.